Supplemental material
Journal of Market Access & Health Policy
Volume 5, 2017 - Issue 1
Article
The perverse impact of external reference pricing (ERP): a comparison of orphan drugs affordability in 12 European countries. A call for policy change
, & 
M. ToumiDepartment of Public Health, Aix-Marseille Université, Marseille, Francehttp://orcid.org/0000-0001-7939-7204
http://orcid.org/0000-0001-7939-7204Related Research Data
Estimating the budget impact of orphan medicines in Europe: 2010 - 2020
Source:
Springer Science and Business Media LLC
Non-profit drug research and development: the case study of Genethon
Source:
Informa UK Limited
Pricing and reimbursement of orphan drugs: the need for more transparency
Source:
Springer Science and Business Media LLC
Congenital diaphragmatic hernia.
Source:
Springer Science and Business Media LLC
European Union Pharmaceutical Markets: A Case for Differential Pricing?
Source:
Informa UK Limited
Access to orphan drugs in Europe: current and future issues
Source:
Informa UK Limited
Access to Orphan Drugs: A Comprehensive Review of Legislations, Regulations and Policies in 35 Countries.
Source:
Public Library of Science (PLoS)
Linking provided by
